What is the role of high-dose chemotherapy in the era of targeted therapies?

Editorial

. 2004 Jun 15;22(12):2263-6.

doi: 10.1200/JCO.2004.02.927. Epub 2004 Apr 26.

Editorial

Gabriel N Hortobagyi. J Clin Oncol. 2004.

. 2004 Jun 15;22(12):2263-6.

doi: 10.1200/JCO.2004.02.927. Epub 2004 Apr 26.

No abstract available

Comment on

High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial.
Zander AR, Kröger N, Schmoor C, Krüger W, Möbus V, Frickhofen N, Metzner B, Schultze W, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Trümper L, Kreienberg R, Carstensen M, Schmidt EH, Jänicke F, Schumacher M, Jonat W. Zander AR, et al. J Clin Oncol. 2004 Jun 15;22(12):2273-83. doi: 10.1200/JCO.2004.07.026. Epub 2004 Apr 26. J Clin Oncol. 2004. PMID: 15111618 Clinical Trial.

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
Vollebergh MA, Lips EH, Nederlof PM, Wessels LFA, Schmidt MK, van Beers EH, Cornelissen S, Holtkamp M, Froklage FE, de Vries EGE, Schrama JG, Wesseling J, van de Vijver MJ, van Tinteren H, de Bruin M, Hauptmann M, Rodenhuis S, Linn SC. Vollebergh MA, et al. Ann Oncol. 2011 Jul;22(7):1561-1570. doi: 10.1093/annonc/mdq624. Epub 2010 Dec 6. Ann Oncol. 2011. PMID: 21135055 Free PMC article. Clinical Trial.
Clinical pharmacokinetics of cyclophosphamide.
de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. de Jonge ME, et al. Clin Pharmacokinet. 2005;44(11):1135-64. doi: 10.2165/00003088-200544110-00003. Clin Pharmacokinet. 2005. PMID: 16231966 Review.